Recombinant Mouse Palmitoyltransferase ZDHHC17 (Zdhhc17)

What is ZDHHC17 and what are its key structural characteristics?

ZDHHC17 (Zdhhc17), also known as Huntingtin Interacting Protein 14 (HIP14), belongs to the family of 23 mammalian DHHC-domain containing palmitoyl transferases (PATs) . Its distinctive structural features include:

• A catalytic DHHC domain essential for its palmitoyl transferase activity

• Ankyrin repeat domains, which are protein interaction motifs involved in substrate recognition

• ZDHHC17 and its paralog ZDHHC13 (HIP14L) are the only mammalian PATs that possess ankyrin repeat domains

• Primarily expressed in the brain, where it localizes to the Golgi apparatus and cytoplasmic vesicles in neurons

The ankyrin repeat domain (ANK17) in ZDHHC17 plays a crucial role in substrate recognition by interacting with ANK binding motifs (zDABM) in substrate proteins, with tryptophan 130 (W130) being critical for these interactions in some cases .

What is the primary catalytic function of ZDHHC17?

The primary catalytic function of ZDHHC17 is to mediate protein S-palmitoylation, which involves the addition of palmitic acid (a 16-carbon fatty acid) to cysteine residues of target proteins via a thioester bond . As a palmitoyl acyltransferase (PAT), ZDHHC17:

• Regulates the palmitoylation and trafficking of several synaptic proteins, including huntingtin (HTT), SNAP-25, GAD-65, PSD-95, and synaptotagmin I

• Undergoes auto-palmitoylation as part of its catalytic cycle, which correlates with its PAT activity

• Demonstrates substrate selectivity, palmitoylating specific proteins such as Smad7 while not modifying related proteins like Smad2, Smad3, Smad4, and Smad6

• Targets specific cysteine residues within its substrates, as shown by the identification of four cysteine residues in Smad7 (Cys202, Cys225, Cys415, and Cys417) that are palmitoylated by ZDHHC17

This enzymatic activity is essential for proper protein localization, trafficking, and function, particularly in neuronal contexts.

How does ZDHHC17 differ from other palmitoyl acyltransferases?

ZDHHC17 possesses several distinctive features that differentiate it from other palmitoyl acyltransferases:

• Substrate selectivity: ZDHHC17 is categorized as a high-selectivity/low-activity enzyme that requires specific recognition of its substrate proteins for successful S-acylation, in contrast to low-selectivity/high-activity isoforms like ZDHHC3 and ZDHHC7

• Structural uniqueness: It contains ankyrin repeat domains for substrate recognition, a feature shared only with its paralog ZDHHC13 among all 23 mammalian PATs

• Huntingtin interaction: ZDHHC17 was first identified as a huntingtin-interacting protein with significantly reduced interaction with mutant HTT

• Dual role of huntingtin: Wild-type HTT not only serves as a palmitoylation substrate for ZDHHC17 but also influences the PAT function of ZDHHC17, potentiating the palmitoylation of other substrates

• Neural enrichment: ZDHHC17 shows enriched expression in the brain and has specialized functions in neuronal contexts, particularly in synaptic protein regulation

This combination of features makes ZDHHC17 particularly important for neuronal function and potentially relevant to neurological disorders.

What mouse models are available for studying ZDHHC17 function?

Several mouse models have been developed to study ZDHHC17 function, each providing unique insights:

• Hip14-/- (complete knockout) mice: Display behavioral, biochemical, and neuropathological defects reminiscent of Huntington's disease, including striatal volume loss and MSN (medium spiny neuron) loss

• Hip14+/- (heterozygous) mice: Show normal brain development, indicating that approximately 50% of functional HIP14 is adequate for normal development

• YAC128 mice: Contain the entire human HTT gene with 128 CAG repeats and have been used to study the relationship between mutant huntingtin and ZDHHC17 function

The Hip14-/- mice display several HD-like phenotypes, including:

• Early striatal volume loss (detectable by embryonic day 17.5)

• Reduced palmitoylation of ZDHHC17 substrates like PSD-95 and SNAP-25

• Motor coordination deficits resembling those seen in HD models

Interestingly, unlike YAC128 mice, the striatal volume loss in Hip14-/- mice does not progressively worsen, suggesting different mechanisms of neurodegeneration .

What techniques are commonly used to detect ZDHHC17-mediated protein palmitoylation?

Several specialized techniques are used to detect and analyze ZDHHC17-mediated protein palmitoylation:

• Acyl-RAC (Resin-Assisted Capture) assay: This method involves treating samples with hydroxylamine to cleave thioester bonds, followed by capture of newly exposed thiols with thiol-reactive resin

• Metabolic labeling with alkynyl palmitic acid: Cells are treated with alkynyl palmitic acid analogs, followed by a click chemistry reaction to attach detection tags to palmitoylated proteins

• Co-immunoprecipitation assays: Used to detect physical interactions between ZDHHC17 and potential substrate proteins

• Auto-palmitoylation assessment: Since ZDHHC17 undergoes auto-palmitoylation as part of its catalytic cycle, measuring its own palmitoylation can be used as a marker of its PAT activity

• Site-directed mutagenesis: To identify specific cysteine residues that are palmitoylated, individual cysteines are mutated and the impact on palmitoylation is assessed

When studying ZDHHC17 activity in YAC128 mouse brains, researchers found that both Hip14 auto-palmitoylation and its ability to palmitoylate substrates like Snap-25 were significantly decreased, demonstrating ZDHHC17 dysfunction in the presence of mutant HTT .

How can researchers identify specific palmitoylation sites in ZDHHC17 substrates?

Identifying specific palmitoylation sites in ZDHHC17 substrates requires a methodical approach:

• Truncation mutant analysis: Creating deletion mutants to determine which regions of the substrate protein contain palmitoylation sites

• Site-directed mutagenesis: Systematically mutating individual cysteine residues to serine and assessing the impact on palmitoylation

• Combined mutations: Creating mutants with multiple cysteine-to-serine substitutions to identify all potential palmitoylation sites

• Click chemistry with mass spectrometry: Using alkynyl palmitate labeling followed by click chemistry and mass spectrometry to directly identify modified residues

This approach was successfully used to identify four cysteine residues in Smad7 (Cys202, Cys225, Cys415, and Cys417) as targets for ZDHHC17-mediated palmitoylation . The research revealed that both the linker region cysteines (C202 and C225) and the C-terminal MH2 cysteines (C415 and C417) are palmitoylated by ZDHHC17, with palmitoylation occurring preferentially in the C-terminal part of Smad7 .

How does huntingtin (HTT) mutation affect ZDHHC17 function in Huntington's disease?

Huntingtin (HTT) mutation has profound effects on ZDHHC17 function, potentially contributing to Huntington's disease pathogenesis:

• Wild-type HTT potentiates the palmitoylation of ZDHHC17 substrates, but this property is lost with mutant HTT containing expanded polyglutamine tracts

• In YAC128 mouse brains, ZDHHC17 protein levels remain unchanged, but its palmitoylation activity is significantly decreased

• Both ZDHHC17 auto-palmitoylation (a marker of PAT activity) and its ability to palmitoylate substrates like SNAP-25 are reduced in the presence of mutant HTT

• ZDHHC17 isolated from YAC128 brains shows significantly reduced PAT activity when assayed for its ability to palmitoylate Snap-25

These findings suggest a model where:

• Mutant HTT does not affect ZDHHC17 expression levels but renders it dysfunctional

• Reduced ZDHHC17 activity leads to decreased palmitoylation of neuronal substrates

• Impaired substrate palmitoylation contributes to synaptic dysfunction and neurodegeneration in HD

The similarities between Hip14-/- mice and YAC128 mice, coupled with the altered function of ZDHHC17 in HD, highlight the potential importance of palmitoylation in HD pathogenesis .

What is the relationship between ZDHHC17 and its paralog ZDHHC13 (HIP14L) regarding compensatory mechanisms?

ZDHHC17 and its closest paralog ZDHHC13 (HIP14L) demonstrate a complex relationship characterized by both overlapping and distinct functions:

This partial functional redundancy enables compensatory mechanisms:

The degree of compensation may be relevant in disease contexts:

• Hip14+/- mice (with 50% ZDHHC17 function) show normal development, suggesting adequate compensation

• In contrast, the more severe phenotypes in YAC128 HD mice may result from dysfunction of both ZDHHC17 and ZDHHC13 in the presence of mutant HTT, limiting compensatory capacity

Understanding these compensatory mechanisms is crucial for developing therapeutic strategies targeting palmitoylation in neurological disorders.

How does ZDHHC17-mediated palmitoylation of Smad7 impact TGF-β signaling?

ZDHHC17-mediated palmitoylation of Smad7 represents a significant regulatory mechanism for TGF-β signaling:

• Smad7 is a negative regulator of TGF-β signaling, and its palmitoylation by ZDHHC17 enhances its inhibitory function

• ZDHHC17 selectively palmitoylates Smad7 at four specific cysteine residues (Cys202, Cys225, Cys415, and Cys417)

• This palmitoylation is specific to Smad7, as other Smad proteins (Smad2, Smad3, Smad4, and Smad6) are not palmitoylated by ZDHHC17

• The interaction between Smad7 and ZDHHC17 primarily involves the C-terminal part of Smad7, with binding slightly increased upon TGF-β stimulation

The biological significance of this palmitoylation includes:

• Enhanced inhibition of TGF-β signaling through Smad7's increased inhibitory function

• Potential implications for various cellular processes regulated by TGF-β, including proliferation, differentiation, and apoptosis

• Possible connections to pathological conditions involving dysregulated TGF-β signaling

This finding extends our understanding of ZDHHC17's functions beyond neurological contexts and suggests that alterations in ZDHHC17 activity, such as those occurring in Huntington's disease, might have consequences through dysregulation of TGF-β signaling pathways .

What are critical controls needed when studying ZDHHC17-mediated palmitoylation?

When studying ZDHHC17-mediated palmitoylation, several critical controls are essential:

• Catalytically inactive ZDHHC17 mutants:

  • Use C467A or C467S mutants that lack PAT activity but maintain protein interactions

  • These serve as negative controls for enzymatic activity while controlling for potential scaffolding functions

• Palmitoylation inhibitor treatment:

  • Include samples treated with broad-spectrum palmitoylation inhibitors like 2-bromopalmitate (2-BP)

  • This confirms that observed modifications are indeed palmitoylation events

• Cysteine-to-serine substrate mutants:

  • Mutate potential palmitoylation sites in substrate proteins

  • This helps identify specific sites of ZDHHC17-mediated palmitoylation

• Hydroxylamine treatment controls:

  • For thioester-specific detection methods, include controls with and without hydroxylamine treatment

  • Hydroxylamine cleaves thioester bonds, confirming that observed modifications are thioester-linked

• Substrate specificity controls:

  • Test related proteins (e.g., testing Smad2, Smad3, Smad4, and Smad6 alongside Smad7)

  • This demonstrates the specificity of ZDHHC17 for particular substrates

In studies of Smad7 palmitoylation by ZDHHC17, researchers effectively used these controls, showing that a catalytically inactive ZDHHC17 mutant (zDHHC17C467S) was unable to palmitoylate Smad7 to the same level as wild-type ZDHHC17, and that 2-BP treatment inhibited S-acylation of Smad7 .

How can researchers distinguish between direct and indirect effects of ZDHHC17 on protein palmitoylation?

Distinguishing between direct and indirect effects of ZDHHC17 on protein palmitoylation requires a multi-faceted approach:

• In vitro palmitoylation assays:

  • Perform palmitoylation assays with purified recombinant ZDHHC17 and substrate proteins

  • Direct enzymatic activity in a defined system provides strong evidence for direct palmitoylation

• Direct binding studies:

  • Demonstrate physical interaction between ZDHHC17 and potential substrates using co-immunoprecipitation

  • The strength of this interaction can provide insights into whether a protein is a direct substrate

• Site-specific mutagenesis:

  • Identify and mutate specific cysteine residues in the substrate that are palmitoylated by ZDHHC17

  • This approach was successfully used to identify four cysteine residues in Smad7 palmitoylated by ZDHHC17

• Catalytically inactive ZDHHC17:

  • Use catalytically inactive ZDHHC17 mutants (e.g., C467A/S) while maintaining normal protein-protein interactions

  • This helps separate enzymatic from scaffolding functions

• Substrate specificity analysis:

  • Test multiple related proteins (as was done with Smad family proteins)

  • Specific palmitoylation of only certain proteins in a family suggests direct enzymatic action

In research on Smad7 palmitoylation, these approaches collectively demonstrated that ZDHHC17 directly palmitoylates Smad7 at specific cysteine residues, while not modifying related Smad proteins .

What factors should be considered when analyzing contradictory findings in ZDHHC17 research?

When analyzing contradictory findings in ZDHHC17 research, several factors should be considered:

• Experimental system differences:

  • Cell types used (neuronal vs. non-neuronal)

  • Expression systems (endogenous vs. overexpression)

  • Detection methods employed (metabolic labeling vs. Acyl-RAC)

• Compensatory mechanisms:

  • Presence and activity levels of other PATs, particularly ZDHHC13

  • In Hip14-/- mice, HTT palmitoylation remains normal despite ZDHHC17 absence, suggesting compensation by other PATs

  • This compensation may vary between experimental systems

• Substrate-specific effects:

  • ZDHHC17 has different effects on various substrates

  • While some substrates like HTT can be palmitoylated by multiple PATs, others like PSD-95 show more specific dependence on ZDHHC17

• Developmental and contextual factors:

  • The early embryonic striatal volume loss observed in Hip14-/- mice does not progressively worsen, suggesting developmental compensation

  • ZDHHC17 function may be differentially regulated in various cellular contexts or disease states

• Experimental timing:

  • Temporal dynamics of ZDHHC17 activity and substrate palmitoylation may lead to different observations at different time points

Understanding these factors can help reconcile seemingly contradictory findings and develop a more nuanced understanding of ZDHHC17 biology and its implications for neurological disorders .